Organ health
We partner with drug developers from preclinical research through post-market surveillance to deliver non-invasive, multi-tissue precision safety monitoring. Together, we can accelerate development timelines, improve safety insights, and reduce risk across the drug development pathway.
Oncology
We partner with diagnostic developers to improve assay performance through our multimodal platforms, Activace™ and Interlace™. By integrating existing technologies with our non-invasive, tumour-naïve liquid biopsy capabilities, partners gain access to deeper biological insights and enhanced accuracy.
Become a partner
Email us at partner@tagomics.com or fill out the form below: